23andMe Halts Therapy Development
This is a news story, published by Yahoo Finance, that relates primarily to Anne Wojcicki news.
Anne Wojcicki news
For more Anne Wojcicki news, you can click here:
more Anne Wojcicki newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
23andMe. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest CEO Anne Wojcicki news, CEO news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
restructuring planReuters
•23andMe cuts 40% of its workforce, discontinues all therapy programs
80% Informative
23andMe said it is reducing about 40% of its workforce and discontinuing further development of all its therapies.
CEO Anne Wojcicki has been trying to take the company private since April .
After Monday 's restructuring plan, company expects annualized cost savings of more than $35 million .
VR Score
89
Informative language
95
Neutral language
55
Article tone
semi-formal
Language
English
Language complexity
64
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links